NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
NBIX on Nasdaq
Shares outstanding
99,605,545
Price per share
$141.83
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
96,832,070
Holdings value
$13,588,446,883
% of all portfolios
0.01%
Share change
-2,217,181
Value change
-$270,037,705
Average buys %
+0%
Average sells %
-0.01%
Number of holders
636
Price from insider filings
$155.09
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 12% $1,274,648,181 12,052,271 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 10% $1,071,315,697 10,129,687 The Vanguard Group 28 Feb 2025
DODGE & COX 5.6% $585,341,834 5,534,624 Dodge & Cox 31 Mar 2025
STATE STREET CORP 4.8% $517,286,649 4,891,137 STATE STREET CORPORATION 31 Dec 2024
As of 30 Sep 2025, NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 636 institutional shareholders filing 13F forms. They hold 96,832,070 shares of 99,605,545 outstanding shares (97%) .

Top 25 institutional shareholders own 65% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 12,706,230 -1.9% 0.03% $1,783,700,523
VANGUARD GROUP INC 9.7% 9,706,559 -1% 0.02% $1,362,606,752
Dodge & Cox 5.6% 5,556,618 -0.18% 0.42% $780,038,035
JPMORGAN CHASE & CO 4.7% 4,730,152 +11% 0.04% $664,018,845
STATE STREET CORP 4.4% 4,346,479 -2.7% 0.02% $610,158,722
PRICE T ROWE ASSOCIATES INC /MD/ 2.9% 2,866,731 -7.1% 0.04% $402,433,000
AQR CAPITAL MANAGEMENT LLC 2.8% 2,773,648 +84% 0.25% $388,435,470
RENAISSANCE TECHNOLOGIES LLC 2.4% 2,418,297 +2.2% 0.45% $339,480,533
GEODE CAPITAL MANAGEMENT, LLC 2% 2,024,825 +3.3% 0.02% $283,499,084
MORGAN STANLEY 1.8% 1,826,936 +0.4% 0.02% $256,465,385
WELLINGTON MANAGEMENT GROUP LLP 1.8% 1,811,762 -11% 0.04% $254,335,149
Bellevue Group AG 1.8% 1,763,105 -3.1% 5.1% $247,504,680
LOS ANGELES CAPITAL MANAGEMENT LLC 1.2% 1,202,756 +62% 0.57% $168,842,887
DEERFIELD MANAGEMENT COMPANY, L.P. 1.2% 1,184,345 +1.4% 2.5% $166,258,351
RTW INVESTMENTS, LP 1.1% 1,062,072 0% 1.8% $149,093,667
MILLENNIUM MANAGEMENT LLC 0.98% 977,210 -18% 0.11% $137,180,740
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 0.95% 948,033 -8.2% 0.35% $133,038,000
NORTHERN TRUST CORP 0.93% 925,714 -0.36% 0.02% $129,951,731
BRAIDWELL LP 0.88% 880,282 -24% 3.7% $123,573,987
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 829,547 +5% 0.02% $116,451,808
CITADEL ADVISORS LLC 0.8% 793,239 -61% 0.09% $111,354,891
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 0.77% 765,237 -45% 0.02% $107,423,971
Bank of New York Mellon Corp 0.76% 761,396 -2.2% 0.02% $106,884,718
DIMENSIONAL FUND ADVISORS LP 0.71% 710,122 +3.8% 0.02% $99,685,572
BANK OF AMERICA CORP /DE/ 0.71% 704,254 +7.8% 0.01% $98,863,177

Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 370,816 $52,259,548 +$25,931,346 $141.83 21
2025 Q3 96,832,070 $13,588,446,883 -$270,037,705 $140.38 636
2025 Q2 98,821,219 $12,420,453,326 +$494,184,481 $125.69 578
2025 Q1 95,485,987 $10,559,467,994 +$7,244,935 $110.60 579
2024 Q4 94,376,685 $12,879,887,685 +$230,192,847 $136.50 596
2024 Q3 93,003,458 $10,720,376,398 -$150,384,737 $115.22 570
2024 Q2 93,636,708 $12,887,512,754 +$47,493,212 $137.67 589
2024 Q1 93,218,731 $12,853,312,563 +$116,424,918 $137.92 580
2023 Q4 92,326,586 $12,160,216,767 +$5,244,067 $131.76 545
2023 Q3 92,001,152 $10,350,228,156 +$38,916,412 $112.50 508
2023 Q2 91,514,317 $8,634,655,568 +$37,920,952 $94.30 452
2023 Q1 90,892,702 $9,194,138,307 +$67,286,199 $101.22 481
2022 Q4 90,124,434 $10,754,797,482 +$104,201,709 $119.44 525
2022 Q3 90,489,863 $9,610,613,890 -$33,115,379 $106.21 451
2022 Q2 89,687,591 $8,740,480,340 -$27,492,643 $97.48 426
2022 Q1 90,130,456 $8,447,849,857 +$146,450,381 $93.75 413
2021 Q4 89,152,258 $7,586,914,975 -$142,540,543 $85.17 389
2021 Q3 90,241,905 $8,655,761,280 -$94,927,615 $95.91 390
2021 Q2 91,390,637 $8,892,923,286 -$379,127,377 $97.32 398
2021 Q1 95,118,085 $9,245,217,222 +$547,907,714 $97.25 410
2020 Q4 89,436,431 $8,572,935,331 -$29,252,870 $95.85 394
2020 Q3 89,711,420 $8,625,616,767 -$165,135,029 $96.16 410
2020 Q2 91,024,593 $11,119,662,216 +$58,260,926 $122.00 409
2020 Q1 90,478,199 $7,833,712,957 +$134,190,014 $86.55 359
2019 Q4 88,959,948 $9,559,971,817 -$103,711,811 $107.49 384
2019 Q3 89,723,577 $8,083,967,833 +$131,837,632 $90.11 326
2019 Q2 88,956,333 $7,509,818,200 +$405,236,838 $84.43 295
2019 Q1 88,419,309 $7,789,441,265 -$73,607,084 $88.10 322
2018 Q4 89,596,633 $6,383,418,413 -$95,226,490 $71.41 320
2018 Q3 88,628,011 $10,894,534,004 -$350,597,450 $122.95 340
2018 Q2 91,900,554 $9,027,143,703 +$3,561,671 $98.24 273
2018 Q1 92,039,747 $7,632,734,396 -$146,781,309 $82.93 262
2017 Q4 93,842,806 $7,281,125,612 -$128,562,595 $77.59 260
2017 Q3 95,978,123 $5,879,367,235 +$103,870,885 $61.28 221
2017 Q2 94,854,554 $4,360,458,912 +$660,704,567 $46.00 220
2017 Q1 85,050,694 $3,682,149,679 +$238,897,265 $43.30 214
2016 Q4 84,375,738 $3,265,417,619 -$80,513,423 $38.70 223
2016 Q3 85,702,329 $4,337,642,435 +$54,561,657 $50.64 238
2016 Q2 84,777,416 $3,856,100,900 -$118,084,536 $45.45 225
2016 Q1 87,607,298 $3,462,890,615 +$138,072,840 $39.55 210
2015 Q4 83,420,495 $4,719,017,664 +$51,306,797 $56.57 216
2015 Q3 82,822,881 $3,294,868,792 -$23,148,713 $39.79 203
2015 Q2 83,373,554 $3,981,499,654 -$77,877,733 $47.76 193
2015 Q1 85,169,982 $3,380,013,692 +$405,563,981 $39.71 171
2014 Q4 75,151,940 $1,678,841,423 +$53,086,515 $22.34 132
2014 Q3 73,295,238 $1,148,500,395 +$43,815,414 $15.67 132
2014 Q2 70,444,189 $1,045,232,097 +$8,065,092 $14.84 124
2014 Q1 69,779,790 $1,123,235,688 +$194,871,032 $16.10 120